PASADENA, Calif. --(BUSINESS WIRE)--Mar. 31, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 29, 2023 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 20, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 3, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023 , at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in
- Achieved Mean Reductions of 88% in C3 and 91% in AH50 PASADENA, Calif. --(BUSINESS WIRE)--Feb. 28, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA
- Achieved Up to 40% Mean Reduction in Liver Fat in PNPLA3 I148M Homozygotes After Single-Dose PASADENA, Calif. --(BUSINESS WIRE)--Feb. 15, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a
- Conference Call and Webcast Today, February 6, 2023 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022 .
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 2, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 25, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022 .
Fibrosis regression observed in 50% of patients receiving fazirsiran Median reductions of 94% of Z-AAT accumulation in the liver and mean reduction of 68% in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results
PASADENA, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023 , at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco .